Here we identify EFR3A as a component of the RAS interactome mediating a positive-feedback circuit that promotes oncogenic KRAS signaling and tumorigenesis, unearthing a potential vulnerability to enhance the antineoplastic activity of KRASG12C-inhibitors for the treatment of pancreatic and possibly other KRAS-mutant cancers. The gene discussed is KRAS; the disease is cancer.